A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03081819|
Recruitment Status : Recruiting
First Posted : March 16, 2017
Last Update Posted : February 28, 2018
A Phase I study of SH003 for evaluate safe dose range in patients with solid cancer.
The first dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated.
The second dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated.
The third dose group receives SH003 for 3 weeks.
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor, Adult||Drug: SH003||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer|
|Actual Study Start Date :||March 30, 2017|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||February 2019|
Participant will take SH003 for 3 weeks.
Herbal medicine for cancer treatment
- Adverse events [ Time Frame: 3 weeks ]Grade 3-4 adverse event using CTCAE v4.03
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03081819
|Contact: Chunhoo Cheon, Doctoremail@example.com|
|Korea, Republic of|
|Ajou University Hospital||Recruiting|
|Suwon, Korea, Republic of, 16499|
|Contact: EUNJIN KWON +82-31-219-6324|